Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M.

J Can Dent Assoc. 2012;78:c85. Review.

2.

Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Bedogni A, Fusco V, Agrillo A, Campisi G.

Oral Dis. 2012 Sep;18(6):621-3. doi: 10.1111/j.1601-0825.2012.01903.x. Epub 2012 Feb 22. No abstract available.

3.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.

Ann Oncol. 2012 May;23(5):1341-7. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10.

PMID:
21986094
4.

Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.

Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O.

J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4. doi: 10.1200/JCO.2011.35.1551. Epub 2011 May 2. No abstract available.

PMID:
21537047
5.

Bisphosphonates in oncology.

Coleman RE, McCloskey EV.

Bone. 2011 Jul;49(1):71-6. doi: 10.1016/j.bone.2011.02.003. Epub 2011 Feb 21. Review.

PMID:
21320652
6.

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.

Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, Solazzo L, Gabriele M, Gaeta GM, Favia G, Peluso F, Colella G.

Oral Oncol. 2011 Mar;47(3):191-4. doi: 10.1016/j.oraloncology.2010.11.007. Epub 2011 Feb 2.

PMID:
21292541
7.

Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.

Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, Bihrle M, Maytal G, August M, Gazelle GS, Swan JS.

Oncologist. 2011;16(1):121-32. doi: 10.1634/theoncologist.2010-0183. Epub 2011 Jan 6.

8.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group..

Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.

9.

Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Migliorati CA, Epstein JB, Abt E, Berenson JR.

Nat Rev Endocrinol. 2011 Jan;7(1):34-42. doi: 10.1038/nrendo.2010.195. Epub 2010 Nov 16. Review.

PMID:
21079615
10.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F.

Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4.

PMID:
20863761
11.

A systematic review of bisphosphonate osteonecrosis (BON) in cancer.

Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT; Bisphosphonate Osteonecrosis Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO)..

Support Care Cancer. 2010 Aug;18(8):1099-106. doi: 10.1007/s00520-010-0882-1. Epub 2010 Apr 22. Review.

PMID:
20411279
12.

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.

Fusco V, Loidoris A, Colella G, Vescovi P, Campisi G.

Breast. 2010 Oct;19(5):432-3; author reply 433-4. doi: 10.1016/j.breast.2010.03.008. Epub 2010 Apr 2. No abstract available.

PMID:
20363135
13.

Bisphosphonates in multiple myeloma.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD003188. doi: 10.1002/14651858.CD003188.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD003188.

PMID:
20238320
14.

American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition.

Colella G, Campisi G, Fusco V.

J Oral Maxillofac Surg. 2009 Dec;67(12):2698-9. doi: 10.1016/j.joms.2009.07.097. No abstract available.

PMID:
19925998
15.

Bisphosphonates and time to osteonecrosis development.

Palaska PK, Cartsos V, Zavras AI.

Oncologist. 2009 Nov;14(11):1154-66. doi: 10.1634/theoncologist.2009-0115. Epub 2009 Nov 8. Review.

16.

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P; European Myeloma Network..

Ann Oncol. 2009 Aug;20(8):1303-17. doi: 10.1093/annonc/mdn796. Epub 2009 May 22. Review.

PMID:
19465418
17.

Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry.

Gliklich R, Wilson J.

J Oral Maxillofac Surg. 2009 May;67(5 Suppl):71-4. doi: 10.1016/j.joms.2009.01.005. Review.

PMID:
19371817
18.

The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

Allen MR, Burr DB.

J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70. doi: 10.1016/j.joms.2009.01.007. Review.

PMID:
19371816
19.

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development.

Ruggiero SL.

J Oral Maxillofac Surg. 2009 May;67(5 Suppl):13-8. doi: 10.1016/j.joms.2008.10.005.

PMID:
19371810
20.

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons..

J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. doi: 10.1016/j.joms.2009.01.009. No abstract available.

PMID:
19371809

Supplemental Content

Support Center